home / stock / brsyf / brsyf news

BRSYF News and Press, Brainsway Ltd Ord From 01/12/26

Stock Information
Company Name: Brainsway Ltd Ord
Stock Symbol: BRSYF
Market: OTC
Website: brainsway.com
Menu
BRSYF BRSYF Quote BRSYF Short BRSYF News BRSYF Articles BRSYF Message Board
Get BRSYF Alerts

News, Short Squeeze, Breakout and More Instantly...
BRSYF - BrainsWay Announces FDA Approval of Neurolief's Proliv(TM)Rx Neuromodulation System for Major Depressive Disorder (MDD)

BURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food and Drug Administratio...
BRSYF - BrainsWay Announces First Coverage Policy for Accelerated Deep TMS(TM)

BURLINGTON, Mass. and JERUSALEM, Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Premera Blue Cross Blue Shield ®...

BRSYF - BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS(TM)

BURLINGTON, Mass. and JERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Optum Behavioral Health, a leading h...

BRSYF - BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

2025-12-01 15:33:28 ET BrainsWay Ltd. (BWAY) Analyst/Investor Day December 1, 2025 10:00 AM EST Company Participants Hadar Levy - Chief Executive Officer Conference Call Participants Michael Gershenzon - Stella MSO, Inc. Owen Muir Jeffrey Cohen - ...
BRSYF - BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS(TM) Treatment December 1, 2025

BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will host a virtual Analyst &...

BRSYF - BrainsWay Launches First Clinical Trial of Deep TMS 360(TM) System for Alcohol Use Disorder

BURLINGTON, Mass. and JERUSALEM, Nov. 17, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced the launch of a multicenter clinical tria...

BRSYF - BrainsWay Receives FDA Clearance of Deep TMS(TM) as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the...
BRSYF - BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript

2025-11-11 10:41:35 ET BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors,...

BRSYF - BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

R evenue increase d 29% to $ 13.5 million in Q3 2025 as compared with Q 3 202 4 Operating income totaled $ 1. 3 million and Adjusted EBITDA rose approximately 80% to $ 2.0 million i...

BRSYF - BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder

BURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U.S. Na...
Previous 10 Next 10